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MR-Trackable Intramyocardial Injection Catheter
P.V. Karmarkar,1* D.L. Kraitchman,1 I. Izbudak,1 L.V. Hofmann,1 L.C. Amado,2
D. Fritzges,1 R. Young,3 M. Pittenger,3 J.W.M. Bulte,1 and E. Atalar1,4
There is growing interest in delivering cellular agents to in-
farcted myocardium to prevent postinfarction left ventricular
remodeling. MRI can be effectively used to differentiate in-
farcted from healthy myocardium. MR-guided delivery of cellu-
lar agents/therapeutics is appealing because the therapeutics
can be precisely targeted to the desired location within the
infarct. In this study, a steerable intramyocardial injection cath-
eter that can be actively tracked under MRI was developed and
tested. The components of the catheter were arranged to form
a loopless RF antenna receiver coil that enabled active tracking.
Feasibility studies were performed in canine and porcine myo-
cardial infarction models. Myocardial delayed-enhancement
(MDE) imaging identified the infarcted myocardium, and real-
time MRI was used to guide left ventricular catheterization from
a carotid artery approach. The distal 35 cm of the catheter was
seen under MRI with a bright signal at the distal tip of the
catheter. The catheter was steered into position, the distal tip
was apposed against the infarct, the needle was advanced, and
a bolus of MR contrast agent and tissue marker dye was in-
jected intramyocardially, as confirmed by imaging and post-
mortem histology. A pilot study involving intramyocardial deliv-
ery of magnetically labeled stem cells demonstrated the utility
of the active injection catheter system. Magn Reson Med 51:
1163–1172, 2004. © 2004 Wiley-Liss, Inc.
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Occlusive coronary artery disease (CAD), leading to myo-
cardial infarction and subsequent congestive heart failure,
is a major cause of morbidity and mortality in the western
world. Because adult cardiomyocytes have a limited abil-
ity to regenerate (1), ischemic events often result in irre-
versible cell injury and concurrent myocardial dysfunc-
tion. Much of the treatment of CAD is aimed at restoring
blood flow to minimize the loss of functional myocytes.
There is growing interest in delivering cellular agents (e.g.,
mesenchymal stem cells (MSCs), myoblasts, etc.) to the
infarcted myocardium to restore healthy myocardial func-
tion (2–7). However, delivering such therapeutic agents by
an intramyocardial approach requires a suitable imaging
modality that can distinguish healthy from infarcted tis-
sue, and guide the procedure.
Interventional cardiology procedures are performed un-
der x-ray fluoroscopic guidance. However, x-ray imaging
techniques cannot distinguish between infarcted and
healthy myocardium. Cardiac electromechanical mapping
systems (e.g., Biosense Webster’s NOGA systems (8,9))
have been used to differentiate between healthy and in-
farcted myocardium. The NOGA system is comprised of a
catheter with three coils and an endocardial-potential
measuring electrode located at the distal tip. During a
typical clinical procedure, three external magnets are
placed at different locations around the patient’s chest.
The catheter is advanced in the left ventricle (LV) and is
moved around to record electrical activity, the motion of
the distal tip, and the distal-tip location data. A 3D, real-
time dynamic reconstruction of the LV, with an assess-
ment of the electrical and mechanical properties of the
myocardium, is then created. Healthy, viable tissue is dif-
ferentiated from infarcted tissue by measuring the endo-
cardial potential and motion at the distal tip of the cathe-
ter. Since this system does not provide an anatomical
image of the heart, the system requires x-ray guidance to
determine the position of the catheter. This procedure is
lengthy, and the quality of the map is operator-dependent.
On the other hand, MRI offers investigators the ability to
readily differentiate healthy from infarcted myocardium
with a high degree of anatomical detail using delayed
contrast-enhanced imaging (10,11). Moreover, real-time
MRI can be used to guide interventional procedures with-
out the use of ionizing radiation. Thus, the clinical efficacy
of an intramyocardial delivery therapy may be improved
by the use of MRI to guide the delivery to the desired
locations in the myocardium.
Currently available injection catheter systems are not
suitable for use in an MR environment, for safety and
procedural reasons. These catheters are constructed with
metallic components, including an injection needle, a
pull-wire, and a braided shaft. These components can be
ferromagnetic and thus may create a susceptibility artifact
and pose a safety hazard in the MR environment. Long
metallic wire components in these catheters can couple
with the external RF fields, causing localized tissue to heat
to unsafe levels (12,13). These catheters, which are also
called passive devices, can be visualized on MR images as
a signal void or susceptibility artifact, but the weak signal
can make determining the precise location of the catheter
body and distal tip problematic. The advantage of passive
tracking is that no specialized hardware, software, or im-
age postprocessing is needed to “see” these devices.
With active catheter tracking, one can accurately track
the position of the catheter without distortion of the un-
derlying anatomy. Active tracking consists of obtaining an
MR signal from the catheter located within the native
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anatomy. Typically, active tracking requires postprocess-
ing of the images to superimpose the image of the coil on
a previously obtained road map image or other hardware
modifications. Different types of RF receiver antennas
(e.g., loop, loopless, opposed solenoid, etc.) can be incor-
porated into intravascular catheters to enable active track-
ing (14–21).
The feasibility of real-time MR-guided intramyocardial
injections was demonstrated by Lederman et al. (22), using
an MRI-modified commercially available injection cathe-
ter (Stiletto™; Boston Scientific, Natick, MA). The
Stilleto™ system consists of three separate components:
two concentric fixed curve guide catheters (9 Fr and 7 Fr),
and an inner spring loaded needle component. The orien-
tation of the guide catheter in the desired direction is
achieved by manipulating the positions of the two concen-
tric guide catheters relative to each other, the needle com-
ponent is then advanced in the guide catheter for in-
tramyocardial delivery of therapeutics (23). Dick et al. (24)
reported the use of a MRI-modified Stiletto™ injection
catheter system in which the guide catheters are arranged
as one RF antenna. The second RF antenna, a microcoil, is
built into the distal tip of the injection needle system. This
creates a high-intensity signal at the distal tip, to enhance
positioning of the needle system before the injection is
performed. The limitation of this system is its inability to
access the basal anatomy of the left ventricle due to the
fixed curve of the LV guide catheters.
In this study, we demonstrate the feasibility of develop-
ing a steerable intramyocardial injection catheter with a
deflectable distal section, which can be actively tracked
and used to deliver cellular therapeutics to the infarcted
myocardium under MRI guidance. The components of the
catheter are arranged to form a “loopless antenna” RF
receiver coil that provides a region of high signal along the
length of the coil to enable active tracking. The distal tip of
the catheter was modified to create a “coiled tip” that
provides high-intensity signal at the distal tip. Thus, the
position of the distal tip as it apposes the infarcted myo-
cardium can be visualized before the needle is advanced
and the therapeutics are delivered directly into the myo-
cardium. The catheter was tested for mechanical, imaging,
and safety performance. As an example of the practical
utility of this device, we show here that magnetically
labeled MSCs can be delivered and imaged in real time in
a canine myocardial infarct model.
THEORY
An intramyocardial injection catheter typically consists of
four metallic components: a pull wire, an anchor wire, an
injection needle, and a braid over the proximal section of
the catheter. The objective of this work was to arrange
these components to form an RF receiver antenna, with a
high-intensity signal at the distal tip of the catheter coil,
while maintaining the desired mechanical properties for
intramyocardial LV injections. In this system, the anchor
wire is 4 cm long and is located in the distal section of the
catheter. It is connected to the distal end of the pull wire
and facilitates the deflection of the distal section. The
anchor wire has virtually no role to play in the electrical
functioning of the catheter, since it is only 4 cm long and
is electrically connected to the distal end of the pull wire.
Different receiver coil configurations were considered, and
a modified loopless antenna design was selected and im-
plemented.
The loopless RF receiver coil dipole antenna, as de-
scribed by Ocali and Atalar (19) is composed of a coaxial
cable with a single metallic core that runs the length of the
cable, and further extends a length of /4 beyond the distal
end of the cable (shielding). At the proximal end of the
coaxial cable, a matching/tuning and decoupling circuit
matches the output of the loopless antenna to the desired
frequency. For this study, we modified the loopless an-
tenna design by constructing a coaxial cable with two
cores (the injection needle and the pull wire) that are
insulated from each other (with a 0.7-mm separation be-
tween the two cores). The copper braid, in the proximal
section of the catheter, forms the shielding of the coaxial
cable. Both the cores extend beyond the shielding into the
distal deflectable section, where they are electrically insu-
lated by separate polymer tubing housings. One core (the
injection needle) is terminated at the distal end of the
catheter. The other core (the pull wire) extends beyond the
length of the catheter, but is coiled back upon itself to
create the “coil tip.” The two cores (i.e., the injection
needle and the pull wire) are electrically connected at the
proximal end of the catheter. A coaxial cable connects the
catheter to the matching tuning interface circuit. The core
of the coaxial cable is connected to the injection needle
and the pull wire, and the shielding of the coaxial cable is
connected to the copper braid of the catheter. Thus, our
intramyocardial injection catheter coil design can be de-
scribed as a modified loopless antenna with a coiled tip.
MATERIALS AND METHODS
Catheter Design
A schematic of the steerable injection catheter is shown in
Fig. 1. The catheter is 80 cm long, 0.3 cm (9 French) in
diameter, and consists of three sections (a distal deflect-
able section (4 cm), a fixed proximal section (70 cm), and
the handle section). The junction of the distal deflectable
section and the proximal nondeflectable section is the
FIG. 1. Schematic of the active injection catheter. The catheter
consists of the following components: 1) distal deflectable section,
2) proximal nondeflectable section, 3) handle section, 4) pull wire, 5)
anchor wire in the distal section, 6) injection needle, 7) deflection
dial, 8) copper braiding (acts as the shielding of the cable), 9)
electrical connections, 10) distal coiled tip, 11) hub to connect the
syringe to the needle, 12) MMCX connector, and 13) proximal shaft
assembly (shown in cross section).
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“point of deflection,” or fulcrum, at which the distal sec-
tion of the catheter deflects. The deflection mechanism is
comprised of a pull wire, an anchor-wire, and the deflec-
tion dial. The pull wire is an 0.035 cm diameter, gold-
plated nitinol wire (NDC, Fremont, CA), and the anchor
wire is a 0.045 cm diameter nitinol wire. For the deflection
mechanism, the anchor wire is 4 cm long and is located in
the distal section of the catheter and fixed at two points:
one at the fulcrum and the other at the distal tip of the
catheter. The pull wire runs along the length of the cath-
eter. The distal end of the pull wire is connected to the
distal end of the anchor wire, and the proximal end of the
pull wire is connected to the deflection dial to control the
extent of deflection. At the distal end of the pull wire, a 10
cm long, 30 American Wire Gauge (AWG) copper magnet
wire (Belden, Inc.) is connected and it coils back upon
itself over the distal tubing, as shown in Fig. 1. The pull
wire, anchor wire, and copper wire from the coiled tip are
electrically connected to form a single conductor unit
(95 cm long). The retractable injection needle (26 AWG,
nitinol tubing, 90 cm long; NDC, Fremont, CA) runs along
the length of the catheter parallel to the pull wire. The
distal end of the needle is a three-face bevel to facilitate
easy advancement into the myocardium. A hub on the
proximal end of the needle serves as a connector to allow
connection with the therapeutic medium-filled syringe.
The needle can be manually advanced beyond the catheter
tip for a distance of 0.5 cm or retracted into the catheter, as
desired.
The desired mechanical and electrical properties of the
catheter were achieved by placing the metallic compo-
nents into different polymeric tubings. The proximal shaft
consists of dual lumen nylon tubing (0.2 cm diameter): one
lumen houses the pull wire, and the other houses the
injection needle (MPE Inc., Minneapolis, MN). The dual
lumen tubing is covered with a copper braid (32 AWG wire
tubular braid; Alpha Wire Company, Elizabeth, NJ). The
copper braid is further insulated with a 0.007 cm thick
polyimide tubing. In the distal section, the pull wire-
anchor wire assembly is housed in thin-walled polytetra-
fluoroethylene (PTFE) tubing (0.09 cm diameter; Zeus Inc.,
SC). The needle is housed in a nylon tube (0.08 cm diam-
eter; Zeus Inc., SC). The two tubings run parallel to each
other and are housed in flexible nylon tubing (0.3 cm
diameter; Putnam Plastics, Inc., NH). The distal and tran-
sition sections of the catheter are bonded with adhesive to
seal the catheter. The housing of the steering handle is
composed of acrylic components. The deflection dial can
be rotated to control the extent of deflection of the distal
section of the catheter. The nylon stopper and the connec-
tor prevent the needle from being extended more than
1 cm beyond the distal tip of the catheter. The needle is
advanced manually as required, and is inside the catheter
otherwise. The balun decoupling and matching-tuning cir-
cuit, as shown in Fig. 2, is implemented to match the
output of the catheter coil at 63.86 MHz. The balun circuit
acts as an RF trap by preventing the shield currents in-
duced on the coaxial cables, connecting the catheter to the
scanner, from reaching the catheter. The decoupling cir-
cuit reduces the length of the catheter by /4 at 63.86 MHz
during RF transmit, when a DC current is applied to shunt
the diode, thus preventing excessive RF deposition and
local temperature rise along the length of the catheter.
Phantom MRI
All phantom and in vivo imaging was performed on a 1.5 T
MR scanner (CV/i; GE Medical Systems, Waukesha, WI).
We determined the signal-to-noise ratio (SNR) and heating
performance while transmitting with the body coil and
receiving with the injection catheter. The SNR properties
of the catheter were tested in a saline (0.9%) phantom
(45 cm long, 15 cm wide, and 10 cm deep). The catheter
was advanced in the phantom for a length of 40 cm and
imaged with a fast spin echo (FSE) pulse sequence (TE 
14 ms, TR  2000 ms, echo train length (ETL)  16, field
of view (FOV)  24 cm, image matrix  256  256, one
excitation number of sequential acquisitions (NSA), and
slice thickness (ST)  5 mm). We tested the signal char-
acteristics of the coil in both straight and deflected states to
determine whether the extent of deflection affected the
signal profile of the catheter. SNR performance along the
length of the catheter was measured on sagittal images
acquired with the FSE sequence. SNR was calculated as
the ratio of mean signal intensity to the standard deviation
(SD) of background signal multiplied by 0.65. We mea-
sured the signal intensity profile as a function of distance
from the catheter by drawing a line one pixel thick across
the sagittal image at the distal tip of the catheter, and at the
fulcrum or “junction” of the modified loopless antenna,
which was 4 cm proximal to the distal tip of the catheter.
The SD of the background signal was measured in a circu-
lar region of interest (500 pixels square in area) outside the
phantom. The SNR profile plot was obtained as a function
of distance from the catheter, as shown in Fig. 3c.
Safety Testing
Heating experiments were performed with the injection
catheter in a cylindrical (20 cm diameter, 50 cm long)
polyacrylamide gel (VWR International) phantom. The
polyacrylamide gel has a conductivity of 0.7 siemens per
meter at 63.86 MHz, which simulates the conductivity of
human tissue. Fiber-optic temperature measurement
probes, with a sensitivity of 0.05°C, were used to measure
the local specific absorption rate (SAR). We determined
FIG. 2. Schematic of the loopless antenna matching/tuning and
decoupling circuit: 1) balun section of the circuit, 2) decoupling
section of the circuit, 3) matching/tuning section of the circuit, 4)
shielded box, 5) ground isolated micro BNC connector, and 6) BNC
connector.
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the SAR by finding the initial slope of temperature rise
(dT/dt) and multiplying by the specific heat of the gel
(4180 J/kg). The SAR was monitored with a four-channel
fiberoptic thermometer that measured the temperature at
each location every 150 ms (UMI4; FISO Technologies,
Quebec, Canada). Three probes were positioned along the
length of the catheter: at the distal tip of the needle (the
needle is advanced 1 cm out of the catheter), at the distal
tip of the catheter, and at the fulcrum or point of deflec-
tion, which is also the junction of the modified loopless
antenna. A fast spoiled gradient echo (FSPGR) pulse se-
quence (TE  1.9 ms, TR  5.8 ms, BW  128 kHz, FOV 
30 cm, image matrix  256  128, NSA  113, four axial
slices, and ST  10 mm) resulted in a total imaging time of
10.06 min. The weight of the phantom was set to 250 lb,
and the scanning parameters resulted in a peak SAR of
3.98 W/kg, as calculated by the scanner software. The
catheter was placed in the polyacrylamide gel phantom,
straight, 5 cm from the edge of the phantom, and was
advanced 45 cm into the gel. The phantom was placed in
the scanner bore such that the catheter was 15 cm off the
isocenter. This catheter position was selected to simulate a
patient in the scanner with the catheter advanced through
the right femoral artery. The following conditions were
tested:
1. Needle advanced with the catheter connected to the
scanner.
2. Needle retracted into the catheter while connected to
the scanner.
3. Catheter disconnected from the scanner with the nee-
dle advanced.
4. Needle advanced out of the catheter, and with a thin
polyimide insulation/coating on the needle (distal
60 cm).
Animal Experiments
The intramyocardial injection catheter was tested in three
closed-chest myocardial infarction animal models (two
canine and one porcine). All of the animal protocols were
reviewed and approved by our institution’s animal care
and use committee. Myocardial infarction was created by
means of a 90-min, closed-chest balloon occlusion of the
left anterior descending (LAD) coronary artery under x-ray
fluoroscopy guidance, followed by perfusion. The in-
tramyocardial injections were carried out 2 weeks postin-
farction. For MRI, the animals were induced with thiopen-
tal (25 mg/kg to effect), intubated, and maintained on
isoflurane general anesthesia with mechanical ventilation.
A carotid artery cut-down to place a 10 F introducer sheath
was performed prior to MRI to facilitate LV catheteriza-
tion, and the animals were heparinized (5000 IU iv).
Animal MRI
The anesthetized animals were placed in right decubitus
with electrocardiogram (ECG) electrodes on their limbs
and chest wall for ECG gating. A four-channel, cardiac
phased-array coil was placed around the chest. Prior to
MR-guided LV catheterization, the location and extent of
myocardial infarction was confirmed by myocardial de-
layed-enhancement (MDE) MRI. Images were acquired
15 min after a 0.2 mmol/kg i.v. bolus of Gd-DTPA (5 cc/s
power injection; MedRad, Indianola, PA) was adminis-
tered. Contiguous short-axis (six to eight slices) and rotat-
ing long-axis slices (20–30° rotation angle) were acquired
with a breath-hold, ECG-gated, saturation pulse recovery
FGRE sequence (TE  3.3 ms, TR  7.4 ms, BW 
31.25 kHz, FOV  28 cm, ST  8 mm, image matrix 
256  190 interpolated to 256  256, flip angle  25°,
inversion time (TI)  200 ms, and two NSA). Breath-
FIG. 3. a: Photograph of the injec-
tion catheter. b: Image acquired by
the catheter in a saline phantom,
with the entire length of the cathe-
ter seen under MR as a bright sig-
nal at the distal tip of the catheter.
c: SNR profile plot along the distal
tip and 4 cm proximal to the distal
tip. The peak SNR at the distal tip
is 800, and the peak SNR 4 cm
proximal to the tip is 500.
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holding was achieved by turning off the ventilator during
the scan. Images were acquired in mid-diastole. Hyperen-
hancing tissue was identified as infarcted myocardium, as
shown in Fig. 4.
LV Catheterization
Images were acquired with the use of a custom phased-
array adapter that combined the signals from the injection
catheter and one element each from the anterior and pos-
terior cardiac phased-array coils. The combined image dis-
playing the cardiac anatomy and the catheter was used to
guide the procedure. The catheter was advanced into the
LV via the carotid introducer, and the distal tip was ap-
posed against the myocardium in the area of interest (in-
farcted myocardium identified by MDE) with a real-time,
steady-state free precession (SSFP) sequence (TR  3.4 ms,
TE  1.2 ms, flip angle  45°, BW  125 kHz, ST  10 mm,
FOV  28 cm, image matrix  128  128 interpolated to
256  256, and NSA  0.5), which resulted in four frames
per second. This sequence was used in conjunction with
interactive scan plane acquisition (i-Drive; General Elec-
tric, Waukesha, WI) to guide the LV catheterization and
visualize the test injections. All images were acquired
without cardiac gating during free breathing.
Once the distal tip of the catheter was apposed against
the myocardium, the needle was advanced into the tissue
to a maximal depth of 0.5 cm, and a 0.5-cc volume injec-
tion of diluted Gd-DTPA (30 mM dilution with physio-
logic saline solution) mixed with a tissue marking dye
(TMD-5; Triangle Biomedical Sciences, Inc., Durham, NC)
was injected into the myocardium. The injection was vi-
sualized by means of an SSFP sequence with the flip angle
increased to 90°, with and without inversion recovery. In
addition, a spoiled gradient echo (SPGR) sequence, with a
flip angle of 90°, without inversion recovery was also
acquired. Finally, a high-resolution, breath-held, ECG-
gated SSFP sequence (TR  4.5 ms, TE  1.8 ms, BW 
125 kHz, FOV  28 cm, image matrix  256  160, ST 
8 mm, and eight views per segment) was acquired with the
use of the cardiac coil to confirm the presence of myocar-
dial contrast injections. In one animal, pilot injections of
MSCs labeled with an iron oxide contrast agent (Feridex;
Berlex Laboratories, Wayne, NJ), were performed follow-
ing a diluted Gd-DTPA test injection. The MSCs were
labeled with the iron contrast marker (Feridex) and poly-
L-lysine, by a technique previously described by Frank et
al. (25) and implemented by Kraitchman et al. (26) to
locate the labeled MSCs in the myocardium by MRI.
Postmortem Techniques
After the animals were humanely euthanized, the hearts
were excised, fixed in formalin, and sectioned either along
the short-axis image planes or a single long-axis imaging
plane, corresponding to the injection locations. The tissue-
dye location was confirmed and compared with the MRI
injection sites. Postmortem heart slices were captured
with a digital camera.
RESULTS
A photograph of the intramyocardial injection catheter
with the modified loopless antenna receiver coil is shown
in Fig. 3a. The impedance of the modified coaxial cable
was 40 ohms when the needle and the pull wire were
connected at the proximal end. The impedance of the
coaxial assembly with individual pull wire and the needle
was 40 ohms and 37 ohms, respectively.
Phantom Studies
An image acquired by the injection catheter, with the needle
advanced 0.5 cm, is shown in Fig. 3b. The distal 35 cm of the
catheter could be seen under MR. In the loopless antenna
design, the shield of the coaxial cable acts as a component of
the antenna, and consequently the MR signal can be seen for
30 cm on the shielding of the coaxial cable. The signal from
the catheter remained consistent whether the catheter was
straight or deflected. The SNR profile plot, which is a func-
tion of signal drop-off from the catheter, is shown in Fig. 3c.
The peak SNR, as measured from the SNR profile plot, was
60% higher at the distal coiled tip compared to the SNR at
4 cm proximal to the distal tip.
Heating Tests
The SAR results are summarized in Table 1. The maxi-
mum local SAR was observed when the catheter was not
connected to the scanner, with the needle advanced 1 cm
out of the catheter and no insulation on the needle. This
SAR was 209 W/kg at the distal tip of the catheter, and
105 W/kg at the distal tip of the needle. Under the same
conditions, when the catheter was connected to the scan-
ner, the maximum SAR observed was 17 W/kg and
FIG. 4. Parallel long-axis MDE
images showing the infarcted
sections of the myocardium, as
indicated by arrows. a–c: The in-
farction extends from the anterior
septum to the lateral wall of the
LV. A saturation recovery FGRE
sequence (TE  3.3 ms, TR 
7.4 ms, BW  31.25 kHz, FOV 
28 cm, ST  8 mm, image ma-
trix  256  190, flip angle  25°,
TI  200 ms, and NSA  2) was
used.
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8.3 W/kg at the distal tip of the needle and catheter, re-
spectively. However, with a thin insulation on the needle,
the SAR was 1.4 W/kg and 2.4 W/kg at the distal tip of the
needle and catheter, respectively. The local SAR at the
junction of the catheter (loopless antenna) was 9 W/kg
with no insulation on the needle, and 5.5 W/kg with the
needle insulated.
Catheter Visualization
The infarcted myocardium was first identified as hyperen-
hancing tissue, by MDE imaging, as shown in Fig. 4. The LV
catheterization was performed with the use of a long-axis
imaging plane that showed the infarcted myocardial sections
and portions of the aortic root, ascending aorta, and descend-
ing aorta (Fig. 5a). The distal 15–25 cm of the catheter could
be seen under MR as a bright signal at the “coiled tip” of the
catheter. The catheter could be seen in dynamic situations
(e.g., when the catheter was deflected to pass the aortic valve
or steered into the long-axis imaging plane). Representative
images demonstrating LV catheterization with MR guidance
and positioning of the distal tip against the infarcted myo-
cardium are shown in Fig. 5. The catheter and the distal tip
could be seen as the catheter was advanced through the
aortic arch, avoiding the descending aorta and into the as-
cending aorta, and traversing the aortic valve into the LV
(Fig. 5b–d). Once in the LV, the catheter was manipulated so
that the distal section of the catheter was in the long-axis
imaging plane (Fig. 5e). The catheter was positioned such
that the distal tip was apposed against the infarcted myocar-
dium in the septal wall (Fig. 5f). Different long-axis views
could be selected, and the catheter could be steered into
these planes to access other myocardial segments (Fig. 6a).
The location of the distal tip against the myocardium was
confirmed by long- and short-axis views.
Injection Visualization
After LV catheterization, injections were performed with
the distal tip of the catheter apposed against the infarcted
Table 1
Local SAR as Measured for Different Conditions
Condition tested
SAR at distal tip of
needle
SAR distal tip of
catheter
SAR at the fulcrum
(junction of loopless
antenna)
No insulation on needle and needle advanced 1 cm 17 W/kg 8.3 W/kg 8.9 W/kg
No insulation on needle and needle retracted in the catheter N/A 8.3 W/kg 8.9 W/kg
No insulation on needle, needle advanced 1 cm and
disconnected from the scanner 105 W/kg 209 W/kg 12.5 W/kg
Needle insulated and needle advanced 1 cm 1.4 W/kg 2.4 W/kg 5.5 W/kg
Needle insulated and retracted in the catheter N/A 2.4 W/kg 5.6 W/kg
FIG. 5. Still frames depict the catheter being steered toward the infarct in the apical septum under real-time MR guidance, a 30-mM
Gd-DTPA injection being administered, and the presence of the injection confirmed by gated, breath-held SSFP imaging. Shown are (a) the
infarcted septal wall as seen under real-time MRI, (b) the catheter being steered in the ascending aorta toward the LV, (c) the distal tip at
the aortic valve, (d) the aortic valve being traversed, (e) the distal tip of the catheter at the apex, (f) a deflectable catheter with the tip flexed
against the infarcted myocardium, (g) a 0.5-cc injection of Gd-DTPA (with tissue marker dye) visualized by increasing the flip angle to 90°
and switching inversion recovery on, and (h) the presence of the injection confirmed by gated, breath-held SSFP imaging (TR  4.5 ms,
TE  1.8 ms, BW  125 kHz, FOV  28 cm, image matrix  256  160, ST  8 mm, and eight views per segment). The imaging sequence
to guide the procedure was as follows: nongated, free-breathing, real-time SSFP with TR  3.4 ms, TE  1.2 ms, flip angle  45°, BW 
125 kHz, ST  10 mm, FOV  28  21 cm, image matrix  128  128, and NSA  0.5.
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myocardium. The distal tip location was confirmed in
short- or long-axis views by high-resolution, ECG-gated,
breath-held, SSFP imaging (Fig. 7a). The needle was then
advanced into the myocardium to a depth of 0.5 cm, and
1.0 cc of diluted Gd-DTPA, mixed with a tissue marker
dye, was injected. We were able to appreciate the en-
hanced visualization of the injection using a high flip
angle combined with an SPGR pulse sequence (Figs. 5g
FIG. 6. Contrast delivery in the lateral wall. a: The
catheter was torqued toward the infarct in the lateral
wall. b: An injection of 30 mM Gd-DTPA under real-
time MR guidance was carried out as indicated by the
arrow. c: The injection was confirmed by gated,
breath-held SSFP imaging, as indicated by the arrow.
d: The location of the injections was confirmed by
postmortem histology, and both of the injections (i.e.,
the septal wall and the lateral wall injections) are seen
in postmortem sections. The imaging sequences are
identical to those used in Fig. 5.
FIG. 7. Gated, breath-held SSFP images of contrast 
tissue marker dye injections in the apical septal wall in
a porcine model. a: Long-axis view image before con-
trast injections. b: The same long-axis views following
the first (contrast  blue dye) injection, where the
contrast is seen as a hyperintense signal indicated by
an arrow. c: Long-axis image visualizing the second
(contrast  green dye) injection (indicated by an ar-
row), with the previous contrast injection seen at the
apex. d: Both injections are confirmed by histology.
Imaging sequences are identical to those used in Fig.
5h.
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and 6b). Postcontrast, SSFP-gated, breath-held, short- and
long-axis images confirmed the presence of the contrast
agent at the injection site, as seen in low-resolution, non-
gated, free-breathing images acquired in real time (Figs. 5h
and 6c). All of the injections were confirmed by postmor-
tem histology, as shown in Figs. 6d and 7d. All 12 diluted
Gd-DTPA injections delivered in two animals were con-
firmed postmortem. However, only nine injections were
visualized during real-time acquisition and high-resolu-
tion SSFP imaging. The tissue marker dye diffused in a
radial fashion from the injection site. In addition, injec-
tions in the septal and lateral walls postmortem are shown
in Figs. 6d and 7d.
To demonstrate a practical application for the catheter,
we injected Feridex-labeled MSCs in vivo into infarcted
canine myocardium. LV catheterization was performed in
a manner identical to that in which the animals received
noncellular injections. The distal tip of the catheter was
positioned within the infarct site, the needle was ad-
vanced, and a test injection of 0.5 cc of diluted Gd-DTPA
was performed and visualized with a 90° flip angle SPGR
sequence. Subsequently, we performed a 0.5-cc injection
of Feridex-labeled MSCs (14  106 MSC s/ml) without
withdrawing the needle. The needle was retracted and the
catheter was advanced in the same plane toward the apex,
and another 0.5 cc injection (containing approximately
4  106 Feridex-labeled MSCs and 3  106 unlabeled
MSCs in a 0.5-cc volume) was performed. The contrast
injection was visualized as hyperintense foci with high-
flip-angle SPGR imaging. With the SSFP real-time imaging
sequence, the labeled stem cells were seen as a hypoin-
tense region (Fig. 8d and e).
DISCUSSION
We developed an active intramyocardial injection catheter
with a deflectable distal section, by arranging/configuring
the components of the catheter to form a modified loopless
antenna. We further demonstrated that the catheter is ca-
pable of accurately delivering cellular therapeutics to the
infarcted myocardium. Moreover, this design is flexible,
and one can incorporate additional needles or deflection
mechanisms without changing the basic design. The SNR
at the distal tip of the catheter was higher (by 60%) than
at the rest of the catheter. Moreover, the signal from the
distal 35-cm length of the catheter facilitated proper posi-
tioning, and the bright tip allowed accurate anatomic
placement. Our method of active tracking has the advan-
tage of utilizing high signal from the catheter to visualize
the catheter within the surrounding tissue/anatomy with-
out the use of specialized hardware or software modifica-
tions. Although passive catheter devices can be seen on
the image itself, the signature of these passive markers is
often insufficient for accurate localization of the catheter
tip, which is important for a therapeutic injection appli-
cation (as demonstrated in this study). Like passive cath-
eter devices, our active catheter approach has the advan-
tage that images of the anatomy and the catheter can be
reconstructed using standard software, with the additional
benefit of precise tip localization.
Devices containing long metallic components have the
potential to heat up in an MR environment. The heating
potential depends upon the length of the components and
the insulation/dielectric thickness surrounding the com-
ponents. Since the long metallic wire components of the
injection catheter are arranged to form a modified loopless
FIG. 8. Representative injections of Feridex-labeled MSCs into the myocardium. a: Still frames depicting the infarcted myocardium
highlighted by MDE imaging and indicated by arrows. b: The distal tip of the catheter is apposed against the infarct in the mid-apical septum
under real-time MR guidance. c: A 30-mM Gd-DTPA injection is carried out and visualized as a hyperintense lesion. d: Feridex-labeled
MSCs (7  106) are injected at the same location. e: The catheter was then repositioned below the previous injection site, and 30 mM
Gd-DTPA were injected. f: Feridex-labeled MSCs (3  106 labeled, and 4  106 unlabeled) are injected at the same location, and both
injections are visualized (the Gd-DTPA injection is bright, and the hypointense Feridex-labeled MSC injection is dark). The lower
concentration of labeled MSCs can be appreciated as a less hypointense lesion in the more apical injection. All of the images were acquired
with the use of a real-time SSFP sequence (TR  3.4 ms, TE  1.2 ms, FA  45° (90° for c and e), BW  125, image matrix  128  128,
NEX  0.5) and the i-Drive interface to guide the procedure.
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receiver antenna, and are decoupled when they are con-
nected to the scanner during RF transmit, the localized
heating observed along the length of the catheter is signif-
icantly lower when the catheter is connected (decoupled)
than when it is disconnected from the scanner (not de-
coupled). When the catheter was not decoupled, the max-
imum SAR (209 W/kg) was observed at the distal tip of the
catheter. This is because the catheter behaves like a linear
conductor in the RF field, and since the pull wire with the
coiled tip is the longest conductor, maximum SAR is ob-
served at the distal tip of the catheter. With the catheter
decoupled during RF transmit, the maximum local SAR
(17 W/kg) was observed at the distal tip of the needle,
indicating the effectiveness of the decoupling circuit.
However, when a needle with a thin insulation was used,
the SAR at the tip of the needle was 1.4 W/kg. This also
suggests that the heating potential can be further reduced
by increasing the insulation thickness over the needle and
the proximal section of the catheter. This change may
further reduce the SNR along the length of the catheter,
making the distal tip appear brighter. However, this would
increase the catheter diameter, which would be a limita-
tion for percutaneous vascular procedures.
The mechanical and imaging performance of the cathe-
ter was satisfactory. The catheter could be easily seen on
MRI and advanced into the LV after it traversed the aortic
valve, and accurately positioned for injection at various
locations in the LV. The mechanical properties of the
catheter make it steerable (deflectable and torquable), so
most of the LV can be accessed. All of the injections of
diluted Gd-DTPA with tissue dye were confirmed post-
mortem. However, 25% of the injections were not visual-
ized with the high-temporal-resolution, low-spatial-reso-
lution, real-time SSFP pulse sequence. Because the long-
axis planes were chosen to optimize conventional
anatomical views (e.g., two- or four-chamber views), in
some cases the imaging planes were not optimized for
injection visualization. Injection visualization may be im-
proved by the use of a nonconventional imaging plane, a
thicker imaging slice, or multislice imaging. Evaluation of
postmortem slices revealed that the spreading of the injec-
tion was nonuniform from the base to the apex and cir-
cumferentially, possibly due to the variation of muscle
sheet planes and fibers within the myocardium. Thus,
unless expectations of the spread of the injection are taken
into account, it is possible that the injection may not be
visualized due to partial volume effects.
Although the catheter was designed to deliver therapeu-
tics to the myocardium, additional modifications to our
prototype can be incorporated to make the procedure more
efficient and precise. In the current design, the distal tip of
the needle is not visible on MRI; a coiled tip on the needle
could be implemented to increase the signal from the
needle and make it visible. A potential advantage of using
an active needle is that it eliminates the need for an MR
contrast injection to confirm the intramyocardial needle
tip location, and thus also eliminates the need for contrast
injection. The catheter could also be modified to measure
an endocardial potential (EP), to verify contact with the
myocardium, and, perhaps, myocardial viability. An RF
splitting circuit, similar to that reported by Susil et al. (27),
could be implemented to measure the local EP signal at the
distal tip of the catheter and confirm the location of the
needle within the myocardium.
CONCLUSIONS
We have successfully designed and developed an in-
tramyocardial injection catheter that can be tracked under
MRI to deliver therapeutics to the myocardium. The cath-
eter was tested for its ability to deliver labeled stem cells
into the targeted regions of the infarcted myocardium.
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